Show simple item record

dc.contributor.authorSimeng, Lin
dc.contributor.authorNicholas, A. Kennedy
dc.contributor.authorAamir, Saifuddin
dc.contributor.authorDiana Muñoz, Sandoval
dc.contributor.authorCatherine, Reynolds
dc.contributor.authorRocio Castro, Seoane
dc.contributor.authorSherine, Kottoor
dc.contributor.authorFranziska, Pieper
dc.contributor.authorKai-Min, Lin
dc.contributor.authorDavid, K. Butler
dc.contributor.authorNeil, Chanchlani
dc.contributor.authorRachel, Nice
dc.contributor.authorDesmond, Chee
dc.contributor.authorClaire, Bewshea
dc.contributor.authorMalik, Janjua
dc.contributor.authorTimothy, J. McDonald
dc.contributor.authorShaji, Sebastian
dc.contributor.authorJames, L. Alexander
dc.contributor.authorLaura, Constable
dc.contributor.authorJames, C. Lee
dc.contributor.authorCharles, D. Murray
dc.contributor.authorAilsa, L. Hart
dc.contributor.authorPeter, M. Irving
dc.contributor.authorGareth-Rhys, Jones
dc.contributor.authorKlaartje, B. Kok
dc.contributor.authorChristopher, A. Lamb
dc.contributor.authorCharlie, W. Lees
dc.contributor.authorDaniel, M. Altmann
dc.contributor.authorRosemary, J. Boyton
dc.contributor.authorJames, R. Goodhand
dc.contributor.authorNick, Powell
dc.contributor.authorTariq, Ahmad
dc.date.accessioned2021-10-20T11:20:29Z
dc.date.available2021-10-20T11:20:29Z
dc.date.issued2021-09-27
dc.identifier.doi10.21203/rs.3.rs-755879/v1
dc.identifier.urihttps://rde.dspace-express.com/handle/11287/622175
dc.description.abstractTo inform healthcare policy for immunosuppressed patients there is a need to define SARS-CoV-2 vaccine responses. Here we report SARS-CoV-2 vaccine-induced antibody and T cell responses in patients treated with anti-tumour necrosis factor (anti-TNF), a commonly used biologic in inflammatory diseases, compared to patients treated with vedolizumab, a gut-specific antibody targeting integrin a4b7 that does not impair systemic immunity. In anti-TNF recipients, the magnitude of anti-SARS-CoV2 antibodies was reduced five-fold, and rapidly decayed towards the seroconversion threshold by 14 weeks after second dose of vaccine. In contrast, anti-SARS-CoV-2 antibodies were sustained up to 16 weeks in vedolizumab-treated patients. Anti-SARS-CoV2 antibody decay was not observed in vaccinated patients previously infected with SARS-CoV-2. T cell responses were absent in one-fifth of anti-TNF and vedolizumab-treated patients after a second dose of either vaccine. Our data have important implications for anti-TNF recipients, including the need for vaccine prioritization, booster doses, and social distancing strategies.
dc.language.isoEng
dc.publisherUnknown
dc.relation.urlhttps://www.scienceopen.com/document?vid=61332d7c-ef69-4193-a377-eb33c1bf23f4
dc.rights© Research Square 2021
dc.subjectSARS-CoV-2
dc.subjectimmune-mediated inflammatory diseases
dc.subjectinflammatory bowel disease
dc.subjectanti-TNF therapy
dc.subjectinfliximab
dc.subjectvedolizumab
dc.subjectimmunosuppressant
dc.subjectvaccine, ChAdOx1 nCoV-19
dc.subjectBNT162b2
dc.subjectdurability
dc.subjectCLARITY
dc.subjectT-Lymphocytes
dc.titleCovid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients
dc.typeJournal Article
dc.identifier.journalResearch Square
dc.description.noteNot held
dc.type.versionepublish
dc.description.admin-noteUnknown


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record